Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.54 |
| ▸ | CNR2 | P34972 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 6/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162606 | 0.87 | ANO1 (0.43) | ANO1CNR2MEN1KMT2ACNR1 | |
| SCHEMBL2162337 | 0.87 | CNR2 (0.54) | CNR2MEN1KMT2ACNR1TNF | |
| SCHEMBL2162416 | 0.86 | CNR2 (0.59) | ANO1CNR2CNR1TRPA1 | |
| SCHEMBL2163131 | 0.85 | CNR2 (0.40) | ANO1CNR2MEN1KMT2ACNR1 | |
| SCHEMBL2162108 | 0.83 | MAPT (0.52) | MEN1KMT2ANOD1 | |
| SCHEMBL2162342 | 0.80 | CNR2 (0.52) | CNR2MEN1KMT2ACNR1 | |
| SCHEMBL2163283 | 0.76 | CNR2 (0.39) | ANO1CNR2MEN1KMT2ACNR1 | |
| SCHEMBL4842211 | 0.75 | MEN1 (0.50) | CNR2MEN1KMT2ACNR1TNF | |
| SCHEMBL2162159 | 0.75 | CNR2 (0.49) | CNR2MEN1KMT2ACNR1 | |
| SCHEMBL4781546 | 0.74 | CNR2 (0.57) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985768-B2 | 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | ANO1 3461/4885CNR2 2/4885MEN1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.